Vasopeptidase inhibitors
- 1 November 2001
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 358 (9292) , 1525-1532
- https://doi.org/10.1016/s0140-6736(01)06584-9
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykininBritish Journal of Pharmacology, 2000
- The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptidesBritish Journal of Clinical Pharmacology, 1997
- Section Review: Cardiovascular & Renal: Recent advances in the development of dual angiotensin-converting enzyme and neutral endopeptidase inhibitorsExpert Opinion on Therapeutic Patents, 1996
- Comparison of Candoxatril and Atrial Natriuretic Factor in Healthy MenHypertension, 1995
- Dual Inhibition of Angiotensin-Converting Enzyme and Neutral Endopeptidase in Rats with HypertensionJournal of Cardiovascular Pharmacology, 1995
- Prevalence of Hypertension in the US Adult PopulationHypertension, 1995
- 7 Combined atriopeptidase inhibition and angiotensin converting enzyme inhibition in hypertensive patientsJournal Of Hypertension, 1994
- Role of neutral endopeptidase in the metabolism of endothelin.Hypertension, 1992
- Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826. An orally active neutral metalloendopeptidase inhibitor.Hypertension, 1990
- Role of angiotensin converting enzyme and other peptidases in in vivo metabolism of kinins.Hypertension, 1989